Skip to main content
Premium Trial:

Request an Annual Quote

Syrrx, Sankyo Pen Drug-Discovery Alliance

NEW YORK, June 13 - Syrrx and Japanese biotech Sankyo have penned a research collaboration that applies Syrrx's high-throughput protein-microcrystallization technology to multiple undisclosed drug targets provided by Sankyo.

 

The deal calls for Tokyo-based Sankyo to provide Syrrx with an upfront tech-access fee. Additionally, Syrrx said it may in the future be allowed to begin its own drug-discovery research.

 

Click here for more information.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.